Therefore, TOPK may act as a prognostic, rather than as a predictive, factor, suggesting that it may be important to consider its expression in metastatic CRC patients with a proficient molecular profile for positive response to anti-EGFR drugs. The gene discussed is EGFR; the disease is colorectal carcinoma.